☆ 4.1 Article

Potent Antibody Response Elicited by a Third Booster Dose of Inactivated COVID-19 Vaccine in Healthy Subjects

VIRAL IMMUNOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Biochemical Research Methods

Evaluation and correlation between SARS-CoV-2 neutralizing and binding antibodies in convalescent and vaccinated subjects

Alessandro Manenti et al.

Summary: This study explored the correlation between neutralizing antibodies and binding antibodies in convalescent patients and vaccinated individuals, and found that the log-values of IgG anti-S antibodies were significantly higher in the vaccinated group compared to convalescent patients. Vaccinated subjects exhibited high levels of anti-S antibodies, while convalescent patients had high levels of both anti-S and anti-N antibodies.

JOURNAL OF IMMUNOLOGICAL METHODS (2022)

添加到收藏夹

Article Cell Biology

Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine

Yihao Liu et al.

Summary: SARS-CoV-2 inactivated vaccines have demonstrated significant efficacy in reducing severe illness and death. Despite a decline in humoral immunity over time, memory B and T cells remain detectable and can provide a quick recall response. A third booster dose enhances the immune response and improves the durability of protective immunity. Additionally, healthcare workers with low serological response to two doses still possess immune memory that can be quickly recalled by a third dose.

CELL DISCOVERY (2022)

添加到收藏夹

Letter Virology

A third booster dose may be necessary to mitigate neutralizing antibody fading after inoculation with two doses of an inactivated SARS-CoV-2 vaccine

Lei Yue et al.

JOURNAL OF MEDICAL VIROLOGY (2022)

添加到收藏夹

Article Infectious Diseases

Evaluation of Immunogenicity by Pseudovirus Neutralization Assays for SARS-CoV-2 Variants after Primary and Booster Immunization

Hui Xie et al.

Summary: This study investigated the immune responses post primary and booster immunization with two doses of inactivated COVID-19 vaccine, highlighting an increase in neutralizing antibodies against variants after booster dose which may enhance vaccine effectiveness.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Infectious Diseases

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

Raches Ella et al.

Summary: The BBV152 vaccine demonstrated tolerable safety outcomes and enhanced immune responses in this clinical trial, leading to selection of both Algel-IMDG formulations for phase 2 immunogenicity trials. Further efficacy trials are warranted to validate the vaccine's effectiveness.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Jennifer M. Dan et al.

Summary: Different components of immune memory to SARS-CoV-2 exhibit distinct kinetics, with antibodies and spike-specific memory B cells remaining relatively stable over 6 months, while CD4(+) T cells and CD8(+) T cells declining with a half-life of 3 to 5 months after infection.

SCIENCE (2021)

添加到收藏夹

Article Immunology

Differential Antibody Response to Inactivated COVID-19 Vaccines in Healthy Subjects

Jiaqi Zhang et al.

Summary: A study showed that 90.7% of vaccinated individuals had NAb seroconversion, with all participants who seroconverted after the first dose being females with relatively high prevaccine estradiol levels. Individuals without seroconversion tended to have lower lymphocyte counts and higher serum SAA levels. Additionally, young vaccine recipients had significantly higher peak NAb titers compared to elderly recipients.

FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes

Yu Guo et al.

Summary: This study identified potent antibodies from COVID-19 convalescent patients that can bind to SARS-CoV-2 Spike protein, with further engineered modifications to enhance their effectiveness and safety. The engineered antibody showed promising results in clearing the virus in a rhesus monkey model of COVID-19, suggesting its potential as a treatment option against SARS-CoV-2 related diseases.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Letter Cell Biology

Time of day influences immune response to an inactivated vaccine against SARS-CoV-2

Hui Zhang et al.

CELL RESEARCH (2021)

添加到收藏夹

Article Medicine, General & Internal

Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults A Randomized Clinical Trial

Nawal Al Kaabi et al.

Summary: This interim analysis of an ongoing randomized trial in the UAE and Bahrain evaluated the efficacy of two inactivated COVID-19 vaccines in preventing symptomatic cases and adverse events in healthy adults. The study found that both vaccines significantly reduced the risk of symptomatic COVID-19 compared to the control group, with efficacy rates of 72.8% and 78.1%. Serious adverse events were rare across all groups.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Letter Immunology

Intensified antibody response elicited by boost suggests immune memory in individuals administered two doses of SARS-CoV-2 inactivated vaccine

Yun Liao et al.

Summary: A study on individuals who received an inactivated SARS-CoV-2 vaccine showed a decrease in neutralizing antibodies over time, but the waning of antibodies does not necessarily indicate a loss of immunity.

EMERGING MICROBES & INFECTIONS (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection

Natalia Sherina et al.

Summary: The study shows that 85% of samples from COVID-19 patients had anti-SARS-CoV-2 antibodies within 4 weeks of symptom onset, while specific IgG antibodies and plasma neutralizing activities remained relatively stable up to 6 months after diagnosis. 80% of samples collected at 6-8 months after symptom onset still had anti-SARS-CoV-2 IgG antibodies, and specific memory B and T cell responses continued to develop and persist.

MED (2021)

添加到收藏夹

Article Microbiology

Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate

Amin Addetia et al.

JOURNAL OF CLINICAL MICROBIOLOGY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders

Emelie Marklund et al.

PLOS ONE (2020)

添加到收藏夹

Review Public, Environmental & Occupational Health

Sex-based differences in immune function and responses to vaccination

Sabra L. Klein et al.

TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination

David Furman et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)

添加到收藏夹

Review Infectious Diseases

The Xs and Y of immune responses to viral vaccines

Sabra L. Klein et al.

LANCET INFECTIOUS DISEASES (2010)

添加到收藏夹

Article Immunology

Randomized, Double-Blind Controlled Phase 3 Trial Comparing the Immunogenicity of High-Dose and Standard-Dose Influenza Vaccine in Adults 65 Years of Age and Older

Ann R. Falsey et al.

JOURNAL OF INFECTIOUS DISEASES (2009)

添加到收藏夹

Article Immunology

Reactogenicity and immunogenicity of an inactivated influenza vaccine administered by intramuscular or subcutaneous injection in elderly adults

IF Cook et al.

VACCINE (2006)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.